High cancer drug prices reduce access to therapy, cause treatment abandonment and financial bankruptcies, as well as severe emotional and family distress.
Katharine Neill, the Alfred C. Glassell, III Postdoctoral Fellow in Drug Policy, explains what you should know about the Justice Department's plan to release 6,000 nonviolent drug offenders from federal prison during four days in October and November.
A new White House initiative to address rising U.S. heroin use will increase funds to pinpoint the sources of heroin as well as hot spots for drug overdoses. Baker Institute Blog: http://bit.ly/1h0W7r2
In this commentary, the authors examine the roots of the United States’ reluctance to embrace universal health care, concluding that it "is neither sound nor ethical in a nation that promulgates fairness and equal opportunity" to deny coverage.
Drug policy has experienced an interesting shift recently. Along with legalization of medical and recreational marijuana, many states are also reducing penalties for nonviolent drug offenses and placing greater focus on treatment for drug users. The emphasis on treatment and rehabilitation for drug users is the result of many factors, including recognition that the drug war has not reduced drug use, a desire to reduce the prison population and save money, and a surge in the rate of overdoses from opioid and heroin use. What remains to be seen is whether the current popularity of drug treatment will become a more permanent feature of drug policy. In this Baker Institute Viewpoints series, five experts on drug policy examine the question, “Is the current emphasis on treatment in drug policy a short-term trend or is it here to stay?”
Katharine Neill Harris, William MartinDecember 19, 2014
In this Baker Institute Viewpoints series, five experts on the marijuana industry examine the question, “What does the future hold for the cannabis industry, in Texas and beyond?”